Solco Healthcare U.S., headquartered in Somerset, New Jersey, is an industry leader in marketing and distributing generic pharmaceuticals. Solco is committed to providing our customers with high quality, cost effective and innovative generic prescription medications. Solco offers a broad range of generic prescription products in many therapeutic categories, including cardiovascular, central nervous system, anti-infectives, pain management and other products. Solco currently markets 45 products, with over 40 products pending approval by the FDA, and a robust R&D pipeline of potential new products. Our products are manufactured in state-of-the-art GMP facilities in the US and overseas using the highest quality assurance standards that meet the FDA regulatory requirements. Solco is a fully owned subsidiary of Prinston Pharmaceutical, Inc. and Zhejiang Huahai Pharmaceutical, leaders in drug development and manufacturing of active pharmaceutical ingredients (API) and finished dosage products. Together we strive to offer greater access to affordable medications that you can trust.
Solco Healthcare is a sales and marketing subsidiary of Prinston Pharmaceuticals
According to IQVIA, Solco has been listed as one of the Top 10 Fastest growing (according to total prescriptions dispensed) generic pharmaceutical companies for the last 5 years and was listed as the #1 Fast Growing Generic pharmaceutical company in 2018.
Prinston Pharmaceutical acquired Solco in 2012
Solco currently markets 45 products with an additional 40+ products pending approval by the FDA
Solco won the “2018 Small to Mid-Sized Generic Supplier of the Year Award” at ClarusOne Sourcing Services (a strategic sourcing group representing McKesson and Walmart)
Solco’s key focus is bringing to market high quality, cost effective generic prescription pharmaceutical products
Developed by Prinston
Prinston Pharmaceutical Inc. engages in developing generic prescription oral solid, injectable, and semi-solid pharmaceutical products for the US market. Prinston was incorporated in 2010 in the state of Delaware. Since its inception, Prinston Pharmaceutical has developed and marketed (under the Solco brand) an impressive group of generic products that provide patients affordable access to otherwise expensive brand name drugs. Solco was acquired by Prinston in March 2012 as the sales and marketing organization of Prinston. This has allowed Prinston and Solco to be ranked as one of the Top-10 fastest growing generic pharmaceutical companies since 2014 and the fastest growing generic company in 2018 (source: IQVIA), a prestigious list that they have been on five years in a row. To continue to supply high quality affordable medicine to the US market, Prinston Pharmaceutical acquired a manufacturing facility based in Charlotte, NC in January 2017. This acquisition allowed Solco/Prinston to introduce additional American made generic products into the market, and expanded the company’s manufacturing capabilities allowing for more new product development in new therapeutic areas.
Prinston’s commitment to providing access to affordable medicine remains as it continues to invest in its R&D and manufacturing capabilities year after year with the goal of filing 10-15 generic drugs (ANDAs) with the FDA each year. With over 40 products pending FDA approval, patients can be assured of a continuous stream of new generic products by Solco/Prinston, making it easier and more affordable for them to get the drugs they need, when they need them.
Backed By Huahai
Our history starts with Solco and Prinston’s parent company Zhejiang Huahai Pharmaceutical. Huahai devotes itself to providing high-quality medicinal and health products around the world with the goal of improving the quality of life for all people. Huahai is a large scale, modern pharmaceutical group that integrates formulations, active pharmaceutical ingredients (API) and intermediates, to deliver high quality generic medications throughout the world. Founded in 1989, Huahai expanded to the United States in 2004 forming Huahai US to sell API to US pharmaceutical customers. The company’s main therapeutic areas include generic prescription cardiovascular, central nervous system, and anti-viral products. Huahai is considered a global leading API and finished dosage manufacturer in these areas.
Huahai is a pioneer in the China pharmaceutical industry becoming the first Chinese pharmaceutical manufacturing company to receive US FDA approval for its finished dosage product marketed in the United States. Today, Huahai is rated as a “Green Factory” by the Ministry of Industry and Information Technology of the P.R.C., supporting its commitment to the World Environment that it proudly serves. Huahai has two API manufacturing sites in China capable of producing 700 and 4,500 metric tons annually. In addition, Huahai’s state-of-the-art finished dosage facility in Linhai, China is capable of producing over 20 billion tablets and capsules annually.
In 2010, Huahai launched Prinston Pharmaceutical, a generic drug delivery company focused on developing generic prescription pharmaceutical products for the US market. Combining Prinston’s strategic drug development capabilities with Huahai’s state of the art, high quality manufacturing capabilities created the opportunity to self-distribute its products throughout the US via the customary generic channels (i.e., wholesalers, distributors, chain stores, etc.).
In 2012, Huahai/Prinston acquired Solco Healthcare US from Legacy Pharmaceuticals. Solco was a new generic pharmaceutical distributor, founded in 2010. Relying on key development partners to launch its products, Solco quickly created a name for itself by offering value driven products with impeccable service and supply. It was these key qualities and a shared vision of offering greater access to affordable medications that convinced Huahai/Prinston to acquire Solco.
Management Team
Solco’s leadership team is focused on putting its customer’s needs first. While cost is a main driver in the generic industry, superior quality and a consistent and reliable supply of product is what continually drives the Solco team to perform at its best. Our leadership team and employees strive to maintain and strengthen our customer relationships to ensure continued growth.
-
Bin He - Chairman and Chief Executive Officer
Bin He has served as the Chairman and Chief Executive Officer of Huahai US, Inc. and its subsidiaries (including Prinston Pharmaceuticals, Solco Healthcare, and Prinston Laboratories) since 2021. Under his leadership, the company has experienced rapid growth both in its top line and bottom line. Mr. He also has served as a Vice President of Huahai US’s parent company, Zhejiang Huahai Pharmaceutical, since 2021; where he oversees all its overseas businesses. From 2014 to present, Mr. He has served as the Chief Executive Officer of Huahai Investment Co., where he is in charge of Huahai’s M&A and equity investment activities worldwide. Mr. He currently serves on the boards of various companies, including Huaota Biologics Pharmaceutical Co., Axcount Pharma GmbH, Eutilex Co. Ltd, Elpis Biopharmaceuticals, and iView Therapeutics. He holds a BS degree in International Trade from Jilin University and a MS degree in Finance from the Shanghai University of International Business and Economics.
-
Gary Xu - Chief Financial Officer
Gary Xu is the Chief Financial Officer, spearheading strategic management of accounting and finance operations while guiding the IT department in digital transformation and ensuring regulatory compliance within the Legal Department. Renowned for his role as a catalyst for new initiatives, Gary is recognized as a cross-functional leader driving company growth.
Before his tenure with Prinston Pharmaceutical Inc, Gary held the position of Chief Accounting Officer and Vice President of Strategic Planning at Designs for Health Inc. for 18 years. He also held senior finance roles at global corporations such as Gerald Metals and Siemon.
Gary’s educational journey includes a bachelor’s degree from the University of Science and Technology of China (USTC) and an MBA from Central Connecticut State University. He holds CPA licensure and the designation of Certified Management Accountant (CMA).
-
Chris Keith - Chief Revenue Officer
Chris Keith is the Chief Revenue Officer at Solco Healthcare. He oversees all aspects of the company’s revenue generation strategies and operations. With a deep understanding of market trends and customer needs, Chris has successfully led his teams to achieve and exceed revenue targets year after year.
Prior to joining Solco, Chris co-founded Éclat Pharmaceuticals (now Avadel) and served as the company’s Executive Vice President of Sales and Marketing. Before Éclat, Chris spent 18 years with ETHEX Corporation, leading the marketing team as the Vice President of Marketing.
Chris holds a Bachelor of Science in Marketing and Management and a Master of Business Administration from the University of Missouri St. Louis.
-
David Ayres - Vice President of Sales
David Ayres is the Vice President of Sales at Solco Healthcare. As the Vice President of Sales, David oversees Solco’s account management team and is responsible for building and maintaining solid customer relationships.
Before joining Solco, David worked for WellPoint Next Rx, a leading pharmacy benefit manager in the U.S., for 16 years.
David holds a Bachelor of Science in Business Administration from the University of Phoenix, underscoring his strong business management and leadership foundation.
-
Bob Rodowicz - Vice President of Commercial Strategy and Operations
Bob Rodowicz serves as the Vice President of Commercial Strategy and Operations at Solco Healthcare. In this position, he manages the Commercial Operations team that deals with demand and supply planning, third-party logistics (3PL) partnerships, customer service, new product launch planning, and DEA quotas. Additionally, Bob works with the Management team on the overall Strategy, including the government business, injectables, and future growth of the organization.
Bob has over 22 years of experience in the generic pharmaceutical industry and has held various leadership positions. Before joining Solco Healthcare, Bob was the Vice President of Sales and Marketing at Athem, LLC.
Bob holds a Bachelor of Science in Marketing from Saint Joseph’s University.